New FDA gene-therapy approvals in 2026?

Market trust

Review trustProviderManual ReviewEvidenceNot Ready

Manual source - last checked Not checked yet

Trust score: In review
Source type: Manual
Provider health: Manual Review
Criteria quality: Warn
Market data quality: Review
Public evidence state: Not Ready
Chart data provenance: Drazill Market Data
Price history freshness: Fresh
Last source check: Not checked yet

Trust methodology

Formula: market-trust-v1.0

Window: Latest market, criteria, provider, and evidence records

Confidence: MEDIUM

Informational only, not trading advice.

- Provider health is market-specific when resolution checks exist and otherwise inferred from configuration.
- Manual-only markets rely on admin review rather than automated source polling.

Trusted creator with 1277 approved markets

Outcome

Chance

Trade

About This Market

Cell and gene therapies keep advancing through the FDA. Resolves to the bucket matching the number of newly approved gene therapies (including gene-edited products) in calendar 2026. Source: FDA.

Source

Official announcement or authoritative source

Market open

May 29, 2026, 03:26 p.m.

Market closes

Jan 8, 2027, 02:26 p.m.

Projected payout

After market closes

New FDA gene-therapy approvals in 2026?

Market trust

About This Market

Related Markets

New FDA gene-therapy approvals in 2026?

Market trust

About This Market

4 to 5

Related Markets

4 to 5